Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
S Hapani, D Chu, S Wu - The lancet oncology, 2009 - thelancet.com
Background Gastrointestinal perforation is a serious adverse event associated with
bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF) widely used in …
bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF) widely used in …
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
S Hapani, D Chu, S Wu - The Lancet Oncology, 2009 - thelancet.com
Background Gastrointestinal perforation is a serious adverse event associated with
bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF) widely used in …
bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF) widely used in …
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.
S Hapani, D Chu, S Wu - The Lancet. Oncology, 2009 - europepmc.org
Background Gastrointestinal perforation is a serious adverse event associated with
bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF) widely used in …
bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF) widely used in …
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
S Hapani, D Chu, S Wu - The Lancet. Oncology, 2009 - pubmed.ncbi.nlm.nih.gov
Background Gastrointestinal perforation is a serious adverse event associated with
bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF) widely used in …
bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF) widely used in …
[HTML][HTML] Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
S Hapani, D Chu, S Wu - Database of Abstracts of Reviews of …, 2009 - ncbi.nlm.nih.gov
The authors concluded that the addition of bevacizumab to cancer therapy significantly
increased the risk of gastrointestinal perforation. Their conclusion reflected the evidence …
increased the risk of gastrointestinal perforation. Their conclusion reflected the evidence …
[引用][C] Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
S HAPANI - Lancet Oncol., 2009 - cir.nii.ac.jp
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab : a meta-analysis
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
S Hapani, D Chu, S Wu - The Lancet Oncology, 2009 - Elsevier
BACKGROUND: Gastrointestinal perforation is a serious adverse event associated with
bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF) widely used in …
bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF) widely used in …
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
S Hapani, D Chu, S Wu - The Lancet Oncology, 2009 - infona.pl
Gastrointestinal perforation is a serious adverse event associated with bevacizumab, an
inhibitor of vascular endothelial growth factor (VEGF) widely used in current cancer …
inhibitor of vascular endothelial growth factor (VEGF) widely used in current cancer …
[引用][C] Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
S HAPANI - Lancet Oncol, 2009 - cir.nii.ac.jp
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab : a meta-analysis
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ …